Ieq Capital LLC Has $3.81 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Ieq Capital LLC grew its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 181.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 28,507 shares of the life sciences company’s stock after buying an additional 18,371 shares during the quarter. Ieq Capital LLC’s holdings in Illumina were worth $3,809,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the company. Private Advisor Group LLC lifted its position in shares of Illumina by 2.1% during the 4th quarter. Private Advisor Group LLC now owns 11,293 shares of the life sciences company’s stock worth $1,509,000 after buying an additional 234 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Illumina during the 4th quarter worth approximately $448,000. Sanctuary Advisors LLC lifted its position in shares of Illumina by 2.8% during the 4th quarter. Sanctuary Advisors LLC now owns 23,424 shares of the life sciences company’s stock worth $3,116,000 after buying an additional 646 shares in the last quarter. Strategic Financial Concepts LLC bought a new position in shares of Illumina during the 4th quarter worth approximately $1,464,000. Finally, Allworth Financial LP lifted its position in shares of Illumina by 720.7% during the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock worth $1,001,000 after buying an additional 6,263 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ILMN shares. Royal Bank of Canada dropped their target price on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Piper Sandler lifted their price target on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and lowered their price target for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Stephens lifted their price target on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Finally, Guggenheim lowered their price target on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $159.45.

Illumina Stock Down 3.1 %

ILMN opened at $94.20 on Friday. The company has a fifty day moving average price of $127.98 and a 200-day moving average price of $134.01. The firm has a market capitalization of $14.92 billion, a P/E ratio of -12.27, a price-to-earnings-growth ratio of 1.70 and a beta of 1.10. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a one year low of $93.50 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.